| Scenario 1 | Scenario 2 | Scenario 3 | Scenario 4 |
---|---|---|---|---|
n of T2D cases (n in top 5%, n in IQR) | 1073 (199, 874) | 1002 (184,818) | 827 (152, 675) | 712 (132, 580) |
Total n (n in top 5%, n in IQR) | 8092 (736, 7356) | 7518 (684, 6834) | 5427 (494, 4933) | 4032 (367, 3665) |
Clinical variables only model | ||||
 C-index | 0.675 | 0.752 | 0.816 | 0.801 |
 CRS HR (CI) (p-val) |  |  |  | 1.71 (1.56–1.88) (1.6e−29) |
PGS only model | ||||
 C-index | 0.608 | 0.607 | 0.603 | 0.608 |
 PGS HR (CI) (p-val) | 2.43 (2.08–2.85) (1.0e−28) | 2.40 (2.04–2.83) (7.1e−26) | 2.43 (2.03–2.91) (3.5e−22) | 2.58 (2.13–3.14) (7.3e−22) |
Combined clinical and PGS model | ||||
 C-index | 0.702 | 0.769 | 0.822 | 0.803 |
 CRS HR (CI) (p-val) |  |  |  | 1.71 (1.56–1.88) (6.6e−29) |
 PGS HR (CI) (p-val) | 2.80 (2.39–3.28) (1.3e−37) | 2.65 (2.25–3.12) (3.3e−31) | 2.40 (2.0–2.88) (4.9e−21) | 2.09 (1.72–2.55) (1.7e−13) |
C-index improvement | 0.027 | 0.017 | 0.006 | 0.002 |
LRT p-value | 8.77E−31 | 6.12E−26 | 5.44E−18 | 7.09E−12 |